GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProMIS Neurosciences Inc (NAS:PMN) » Definitions » EPS without NRI

PMN (ProMIS Neurosciences) EPS without NRI : $-0.72 (TTM As of Jun. 2024)


View and export this data going back to 2005. Start your Free Trial

What is ProMIS Neurosciences EPS without NRI?

ProMIS Neurosciences's earnings per share without non-recurring items for the three months ended in Jun. 2024 was $-0.13. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.72.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -6.60% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -2.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for ProMIS Neurosciences's EPS without NRI or its related term are showing as below:

PMN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -31.6   Med: 13   Max: 35.1
Current: -6.6

During the past 13 years, ProMIS Neurosciences's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 35.10% per year. The lowest was -31.60% per year. And the median was 13.00% per year.

PMN's 3-Year EPS without NRI Growth Rate is ranked worse than
64.55% of 1244 companies
in the Biotechnology industry
Industry Median: 4.75 vs PMN: -6.60

ProMIS Neurosciences's EPS (Diluted) for the three months ended in Jun. 2024 was $-0.13. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.70.

ProMIS Neurosciences's EPS (Basic) for the three months ended in Jun. 2024 was $-0.13. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.70.


ProMIS Neurosciences EPS without NRI Historical Data

The historical data trend for ProMIS Neurosciences's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProMIS Neurosciences EPS without NRI Chart

ProMIS Neurosciences Annual Data
Trend Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.38 -0.94 -1.50 -3.14 -1.14

ProMIS Neurosciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.34 -0.20 -0.20 -0.19 -0.13

Competitive Comparison of ProMIS Neurosciences's EPS without NRI

For the Biotechnology subindustry, ProMIS Neurosciences's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProMIS Neurosciences's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProMIS Neurosciences's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where ProMIS Neurosciences's PE Ratio without NRI falls into.



ProMIS Neurosciences EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ProMIS Neurosciences  (NAS:PMN) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


ProMIS Neurosciences EPS without NRI Related Terms

Thank you for viewing the detailed overview of ProMIS Neurosciences's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


ProMIS Neurosciences Business Description

Traded in Other Exchanges
Address
1920 Yonge Street, Suite 200, Toronto, ON, CAN, M4S 3E2
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
Executives
Madge K. Shafmaster director C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Patrick D. Kirwin director C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Larry Douglas Altstiel officer: Chief Medical Officer C/O NEUROTROPE, INC., 50 PARK PLACE, SUITE 1401, NEWARK NJ 07102
Daniel E. Geffken officer: Chief Financial Officer DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Jeremy M. Sclar 10 percent owner 33 BOYLSTON STREET, SUITE 3000, CHESTNUT HILL MA 02467
Gail M Farfel director, officer: Chief Executive Officer 142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Max A. Milbury officer: Principal Accounting Officer C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Gavin T. Malenfant officer: Chief Operating Officer C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Neil Cashman director, officer: Chief Scientific Officer C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Johanne Kaplan officer: Chief Development Officer PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Eugene Williams director, officer: Chairman and CEO C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Richard J. Gregory director 830 WINTER STREET, WALTHAM MA 02451
Neil K Warma director C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
William W Wyman director 4 N. BALCH STREET, HANOVER NH 03755
Josh Mandel-brehm director C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2